Van Eck Associates Corp Seagen Inc. Transaction History

Van Eck Associates Corp

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$191.51 - $216.16 $1.64 Million - $1.85 Million	-8,556 Reduced 7.64%	103,373 $21.9 Million
Q2 2023 Aug 03, 2023	SELL	$187.64 - $206.25 $115,773 - $127,256	-617 Reduced 0.55%	111,929 $21.5 Million
Q1 2023 May 03, 2023	SELL	$127.59 - $203.08 $3.91 Million - $6.22 Million	-30,610 Reduced 21.38%	112,546 $22.8 Million
Q4 2022 Feb 08, 2023	BUY	$117.37 - $139.17 $5.18 Million - $6.14 Million	44,136 Added 44.57%	143,156 $18.4 Million
Q3 2022 Oct 27, 2022	SELL	$135.27 - $180.11 $5.88 Million - $7.83 Million	-43,474 Reduced 30.51%	99,020 $13.5 Million

Q2 2022 Aug 03, 2022	BUY	$108.81 - $179.33 $1.04 Million - $1.71 Million	9,533 Added 7.17%	142,494 $25.2 Million
Q1 2022 May 10, 2022	SELL	$119.61 - $157.85 $682,973 - $901,323	-5,710 Reduced 4.12%	132,961 $19.2 Million
Q4 2021 Jan 26, 2022	SELL	$142.57 - $190.86 $2.67 Million - $3.57 Million	-18,703 Reduced 11.88%	138,671 $21.4 Million
Q3 2021 Nov 03, 2021	SELL	$142.45 - $169.82 $1.29 Million - $1.53 Million	-9,032 Reduced 5.43%	157,374 $26.7 Million
Q2 2021 Aug 10, 2021	BUY	$135.08 - $161.1 $2.43 Million - $2.9 Million	18,024 Added 12.15%	166,406 $26.3 Million
Q1 2021 May 13, 2021	BUY	$137.51 - $190.8 $4.23 Million - $5.86 Million	30,731 Added 26.12%	148,382 $20.6 Million
Q4 2020 Feb 09, 2021	BUY	$164.63 - $211.93 $1.49 Million - $1.92 Million	9,073 Added 8.36%	117,651 $20.6 Million
Q3 2020 Nov 12, 2020	BUY	$145.95 - $195.69 $15.8 Million - $21.2 Million	108,578 New	108,578 $21.2 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.